Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+

  Multiple Sclerosis

  Free Subscription

Articles published in Clin Ther

Retrieve available abstracts of 9 articles:
HTML format
Text format

Single Articles

    May 2019
  1. REN J, Ascencio M, Raimondi T, Rainville EC, et al
    Association Between Exposure of Ipratropium and Salmeterol and Diagnosis of Multiple Sclerosis: A Matched Case-control Study.
    Clin Ther. 2019 May 22. pii: S0149-2918(19)30242.
    PubMed     Text format     Abstract available

    February 2019
  2. VERMERSCH P, Martinelli V, Pfleger C, Rieckmann P, et al
    Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Clin Ther. 2019;41:249-260.
    PubMed     Text format     Abstract available

    November 2018
  3. KRESA-REAHL K, Repovic P, Robertson D, Okwuokenye M, et al
    Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-Reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
    Clin Ther. 2018 Nov 20. pii: S0149-2918(18)30506.
    PubMed     Text format     Abstract available

    May 2018
  4. VISARIA J, Thomas N, Gu T, Singer J, et al
    Understanding the Patient's Journey in the Diagnosis and Treatment of Multiple Sclerosis in Clinical Practice.
    Clin Ther. 2018 May 23. pii: S0149-2918(18)30186.
    PubMed     Text format     Abstract available

    March 2018
  5. KITA M, Fox RJ, Gold R, Giovannoni G, et al
    Corrigendum to 'Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (
    Clin Ther. 2018 Mar 7. pii: S0149-2918(18)30055.
    PubMed     Text format    

    December 2017
  6. MOTL RW, Sandroff BM
    Exercise as a Countermeasure to Declining Central Nervous System Function in Multiple Sclerosis.
    Clin Ther. 2017 Dec 26. pii: S0149-2918(17)31106.
    PubMed     Text format     Abstract available

    July 2017
  7. FERNANDEZ O, Giovannoni G, Fox RJ, Gold R, et al
    Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Clin Ther. 2017 Jul 24. pii: S0149-2918(17)30765.
    PubMed     Text format     Abstract available

    February 2017
  8. SOINI E, Joutseno J, Sumelahti ML
    Cost-Utility of First-Line Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Clin Ther. 2017 Feb 13. pii: S0149-2918(17)30074.
    PubMed     Text format     Abstract available

  9. VAN AMERONGEN G, Kanhai K, Baakman AC, Heuberger J, et al
    Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Delta9-Tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis.
    Clin Ther. 2017 Feb 9. pii: S0149-2918(17)30054.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.